A Study of MZE782 in Adults With PKU

← catalyst calendar

NCT07694440 · readout ≤ 499 d

Sponsored by Maze Therapeutics (industry) · MAZE — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

38estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-23

actual

When the study began enrolling

Primary completion

Dec 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2028

estimated

The whole study's end, after follow-up

First posted

2026-07-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Phenylketonuria (PKU)

Interventions

Drug: MZE782
Other: Placebo
Drug: MZE782

Primary outcomes

what the primary-completion date above is the date OF

Safety and tolerability based on incidence of adverse events (AEs)

measured Week 0 to Week 17

For Cohorts 1A and 1B: Absolute change in plasma Phe levels from Baseline to the mean of plasma Phe levels

measured Baseline and Weeks 2, 3, and 4

Permalink · MAZE's whole pipeline · Catalyst calendar · Every registered study · What changed